OncoMatch/Clinical Trials/NCT06894979
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Is NCT06894979 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ATM Kinase Inhibitor AZD1390 for childhood astrocytoma.
Treatment: ATM Kinase Inhibitor AZD1390 — This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving AZD1390 with radiation may be safe, tolerable, and/or effective in treating pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Excluded: BRAF V600E
Patients with BRAFV600E mutations are excluded
Allowed: H3F3A (H3 K27M) K27M mutation
diffuse midline glioma, H3 K27-altered
Allowed: H3F3A (H3 K27M) G34 mutation
diffuse hemispheric glioma, H3 G34-mutant
Allowed: IDH1 mutation
astrocytoma; IDH-mutant
Allowed: IDH1 wild-type
glioblastoma, IDH-wildtype
Prior therapy
Must have received: surgery
Prior therapy for any cancer diagnosis (including radiation) is not allowed with the exception of surgery and/or corticosteroids.
Must have received: corticosteroids
Prior therapy for any cancer diagnosis (including radiation) is not allowed with the exception of surgery and/or corticosteroids.
Cannot have received: radiation therapy
Patients with a history of radiotherapy as part of anti-cancer therapy are excluded
Cannot have received: any anti-cancer therapy (other than surgery/corticosteroids)
Prior therapy for any cancer diagnosis (including radiation) is not allowed with the exception of surgery and/or corticosteroids.
Lab requirements
Blood counts
ANC ≥ 1000/uL; Platelet count ≥ 100,000/uL (transfusion independent ≥ 7 days); Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
Kidney function
Serum creatinine by age/sex threshold OR 24h urine creatinine clearance ≥ 70 mL/min/1.73 m^2 OR GFR ≥ 70 mL/min/1.73 m^2 (direct measurement required)
Liver function
Bilirubin ≤ 1.5 x ULN for age (≤ 3.0 x ULN if Gilbert's); ALT/AST ≤ 3 x ULN (≤ 5 x ULN if tumor involvement); Albumin ≥ 2 g/dL
Cardiac function
No evidence of clinically significant cardiac dysfunction or prolonged QTc (> 450 msec) on baseline EKG
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL... Platelet count ≥ 100,000/uL... Hemoglobin ≥ 8.0 g/dL... Bilirubin ≤ 1.5 x ULN... ALT ≤ 3 x ULN... AST ≤ 3 x ULN... Albumin ≥ 2 g/dL... Serum creatinine by age/sex... GFR ≥ 70 mL/min/1.73 m^2... No evidence of clinically significant cardiac dysfunction or prolonged corrected QT interval (QTc) (> 450 msec) on baseline electrocardiogram (EKG)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Alabama · Birmingham, Alabama
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital of Orange County · Orange, California
- Children's Hospital Colorado · Aurora, Colorado
- Children's National Medical Center · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify